Wang TS, Jing LJ. Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction. World J Psychiatry 2024; 14(5): 644-652 [PMID: 38808092 DOI: 10.5498/wjp.v14.i5.644]
Corresponding Author of This Article
Tian-Shu Wang, PhD, Doctor, Department of Neurology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, Henan Province, China. fccwangts@zzu.edu.cn
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. May 19, 2024; 14(5): 644-652 Published online May 19, 2024. doi: 10.5498/wjp.v14.i5.644
Table 1 General data, n (%)
Factors
Observation group (n = 65)
Control group (n = 59)
χ2
P value
Sex
0.002
0.065
Male
35 (53.85)
32 (54.24)
Female
30 (46.15)
27 (45.76)
Age (yr)
0.026
0.871
≤ 65
31 (47.69)
29 (49.15)
> 65
34 (52.31)
30 (50.85)
BMI (kg/m2)
0.039
0.844
≤ 23
32 (49.23)
28 (47.46)
> 23
33 (50.77)
31 (52.54)
History of smoking
0.009
0.923
Yes
38 (58.46)
35 (59.32)
No
27 (41.54)
24 (40.68)
Diabetes
0.009
0.993
Yes
32 (49.23)
29 (49.15)
No
33 (50.77)
30 (50.85)
Hypertension
0.084
0.772
Yes
38 (58.46)
36 (61.02)
No
27 (41.54)
23 (38.98)
Drinking habit
0.001
0.981
Yes
42 (64.62)
38 (64.41)
No
23 (35.38)
21 (35.59)
Table 2 Comparison of therapeutic efficacy, n (%)
Curative effect
Observation group (n = 65)
Control group (n = 59)
χ2
P value
Markedly effective
38 (58.46)
25 (42.37)
-
-
Effective
24 (36.92)
21 (35.59)
-
-
Ineffective
3 (4.62)
13 (22.03)
-
-
Effectiveness of treatment
62 (95.38)
46 (77.97)
8.350
0.004
Table 3 Comparison of neurological deficit scores
Time
Observation group (n = 65)
Control group (n = 59)
t
P value
Before treatment
22.18 ± 1.01
22.24 ± 1.13
0.312
0.755
After treatment
11.25 ± 1.05
17.00 ± 1.10
29.772
< 0.001
Table 4 Comparison of daily living ability
Time
Observation group (n = 65)
Control group (n = 59)
t
P value
Before treatment
52.34 ± 1.53
52.42 ± 1.80
0.267
0.790
After treatment
67.20 ± 1.54
59.37 ± 1.68
27.079
< 0.001
Table 5 Comparison of cognitive function
Time
Observation group (n = 65)
Control group (n = 59)
t
P value
Before treatment
21.06 ± 1.07
21.15 ± 1.22
0.438
0.663
After treatment
24.94 ± 1.09
23.20 ± 1.00
9.232
< 0.001
Table 6 Comparison of adverse reactions during medication, n (%)
Adverse reactions
Observation group (n = 65)
Control group (n = 59)
χ2
P value
Skin ecchymosis
2 (3.08)
1 (1.69)
-
-
Black stool
2 (3.08)
2 (3.39)
-
-
Dizziness
3 (4.62)
1 (1.69)
-
-
Stomach bleeding
2 (3.08)
1 (1.69)
-
-
Total incidence
9 (13.85)
5 (8.47)
0.891
0.345
Table 7 Comparison of the quality of life after treatment
Quality of life
Observation group (n = 65)
Control group (n = 59)
t
P value
Body function
62.28 ± 1.39
49.49 ± 1.60
47.625
< 0.001
Social function
65.09 ± 1.44
51.07 ± 1.57
51.868
< 0.001
Physiological state
63.25 ± 1.35
52.00 ± 1.13
50.041
< 0.001
Mental state
65.09 ± 1.38
53.19 ± 1.33
48.788
< 0.001
Citation: Wang TS, Jing LJ. Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction. World J Psychiatry 2024; 14(5): 644-652